B+
Bull case
25%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
AARD
Aardvark TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The $73.9 million cash position and projected runway into late 2027 give Aardvark time to analyze HERO/OLE data and pursue an FDA-defined path. A constructive data interpretation or clinical-hold resolution could restore material option value.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +23.7.
What can break
HERO and OLE were terminated, and the company does not currently intend to resume them as previously designed. [#SEC-8K-2026-08-11]
Momentum
91
Value
41
Sentiment
45
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.50 · Bull $9.00 · Bear $2.50Analysis 2026-09-12; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-12 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $10.13
Why
Momentum91 · Δ7d -5.3
Value41 · Δ7d -0.0
Sentiment45 · Δ7d +23.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +23.7.
Contradictions & invalidation
- • HERO and OLE were terminated, and the company does not currently intend to resume them as previously designed. [#SEC-8K-2026-08-11]
- • Investor-law-firm solicitation headlines may pressure sentiment, but the packet does not establish an adjudicated claim or company liability.
- • ARD-101 is under a full FDA clinical hold, HERO and OLE were terminated, and management does not currently intend to resume them as previously designed.
Catalyst clock
2026-09-30
HERO/OLE data assessment and ARD-101 decision
Lead driver: Sentiment · See AI snapshot
Momentum
91
9% active weight
Current posture
7d trendSoftening
Δ7d
-5.3
Δ21d
-5.3
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-5.2
Sentiment
45
62% active weight
Current posture
7d trendImproving
Δ7d
+23.7
Δ21d
+17.2
Why this grade
Composite grade D. Momentum 91.2 / Value 41.2 / Sentiment 45.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-12. Scenario method
Most likely
B
Base case
40%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$147.5M
Beta
-
Shares Out
21.88M
P/E (TTM) · Derived
-2.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.12
Rev YoY
-
EPS YoY
-0.6%
Gross Margin
-
Op Margin
-
Net Debt
-$109.59M
Current Ratio
12.63
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data